199 related articles for article (PubMed ID: 24704030)
1. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
[TBL] [Abstract][Full Text] [Related]
2. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
[TBL] [Abstract][Full Text] [Related]
3. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
5. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
[TBL] [Abstract][Full Text] [Related]
6. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
8. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
9. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
Janto K; Prichard JR; Pusalavidyasagar S
J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
11. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
12. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
Koebisu M; Koyama N; Nishida M; Muramoto K
Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
[TBL] [Abstract][Full Text] [Related]
13. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
14. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
15. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
[TBL] [Abstract][Full Text] [Related]
16. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.
Gotter AL; Winrow CJ; Brunner J; Garson SL; Fox SV; Binns J; Harrell CM; Cui D; Yee KL; Stiteler M; Stevens J; Savitz A; Tannenbaum PL; Tye SJ; McDonald T; Yao L; Kuduk SD; Uslaner J; Coleman PJ; Renger JJ
BMC Neurosci; 2013 Aug; 14():90. PubMed ID: 23981345
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment.
Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S
Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
19. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
20. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
Skudlarek JW; DiMarco CN; Babaoglu K; Roecker AJ; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Wuelfing WP; Garson SL; Fox SV; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Kuduk SD; Coleman PJ
Bioorg Med Chem Lett; 2017 Mar; 27(6):1364-1370. PubMed ID: 28216403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]